|
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. |
|
|
Consulting or Advisory Role - Innovent Biologics |
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst) |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Genentech/Roche (I); Merck; MERCK (I); Novartis; Seagen |
Research Funding - Abbvie (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Infinity Pharmaceuticals (Inst); Klus Pharma (Inst); Lilly (Inst); Livzon (Inst); Merck (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Plexxikon (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Gilead Sciences (I) |
Research Funding - Forty Seven (Inst); Merck Sharp & Dohme (Inst); Regeneron (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Clovis Oncology |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; Guardant Health; Incyte; Janssen; Janssen Oncology; Karyopharm Therapeutics; Merck Sharp & Dohme (Inst); Tesaro |
Speakers' Bureau - Clovis Oncology; Genentech |
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Immunogen (Inst); Janssen (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Pfizer (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst) |
|
|
Honoraria - Curio Science |
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); Compugen (Inst); Corcept Therapeutics (Inst); Eisai (Inst); Forty Seven (Inst); Genentech (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Leap Therapeutics (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst) |
(OPTIONAL) Uncompensated Relationships - TTC Oncology |
|
|
Employment - Forty Seven; Kaiser Permanente (I) |
Stock and Other Ownership Interests - Forty Seven |
|
|
|
Stock and Other Ownership Interests - Abbvie; BeiGene |
|
|
|
Stock and Other Ownership Interests - Forty Seven |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Merck KGaA |
Patents, Royalties, Other Intellectual Property - Merck KGaA |
Travel, Accommodations, Expenses - Merck KGaA |
|
|
|
Stock and Other Ownership Interests - Forty Seven |
|
|
|
|
Stock and Other Ownership Interests - Forty Seven; Hepatx |
|
Consulting or Advisory Role - Chimera Bioengineering |
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc. |
Travel, Accommodations, Expenses - Forty Seven |
|
|
|
|
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson |
Consulting or Advisory Role - Biomotiv |
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc. |
Travel, Accommodations, Expenses - Forty Seven |
|
|
Honoraria - Prime Oncology; Research To Practice |
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Clovis Oncology; Eisai; Genentech/Roche; Immunogen; Janssen Oncology; Merck; OncoMed; Pfizer/EMD Serono; Samumed; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics |
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst) |